173 related articles for article (PubMed ID: 35201680)
1. Diagnosis and management of TRK fusion cancer.
Kummar S; Italiano A; Brose MS; Carlson JJ; Sullivan SD; Lassen U; Federman N
Am J Manag Care; 2022 Jan; 28(2 Suppl):S15-S25. PubMed ID: 35201680
[TBL] [Abstract][Full Text] [Related]
2. Tropomyosin receptor kinase (TRK) biology and the role of NTRK gene fusions in cancer.
Amatu A; Sartore-Bianchi A; Bencardino K; Pizzutilo EG; Tosi F; Siena S
Ann Oncol; 2019 Nov; 30(Suppl_8):viii5-viii15. PubMed ID: 31738427
[TBL] [Abstract][Full Text] [Related]
3. Timing of NTRK Gene Fusion Testing and Treatment Modifications Following TRK Fusion Status Among US Oncologists Treating TRK Fusion Cancer.
Klink AJ; Kavati A; Gassama AT; Kozlek T; Gajra A; Antoine R
Target Oncol; 2022 May; 17(3):321-328. PubMed ID: 35716252
[TBL] [Abstract][Full Text] [Related]
4. Testing algorithm for identification of patients with TRK fusion cancer.
Penault-Llorca F; Rudzinski ER; Sepulveda AR
J Clin Pathol; 2019 Jul; 72(7):460-467. PubMed ID: 31072837
[TBL] [Abstract][Full Text] [Related]
5. Recommended testing algorithms for NTRK gene fusions in pediatric and selected adult cancers: Consensus of a Singapore Task Force.
Lim KHT; Kong HL; Chang KTE; Tan DSW; Tan IBH; Mohamad F; Soh SY; Pang BN; Soo RA; Choo SP; Hsieh WS; Aung L
Asia Pac J Clin Oncol; 2022 Aug; 18(4):394-403. PubMed ID: 34806337
[TBL] [Abstract][Full Text] [Related]
6. Neurotrophic tyrosine receptor kinase fusion in pediatric central nervous system tumors.
Lang SS; Kumar NK; Madsen P; Gajjar AA; Gajjar E; Resnick AC; Storm PB
Cancer Genet; 2022 Apr; 262-263():64-70. PubMed ID: 35108662
[TBL] [Abstract][Full Text] [Related]
7. NTRK fusions in thyroid cancer: Pathology and clinical aspects.
Ma Y; Zhang Q; Zhang K; Liang Y; Ren F; Zhang J; Kan C; Han F; Sun X
Crit Rev Oncol Hematol; 2023 Apr; 184():103957. PubMed ID: 36907364
[TBL] [Abstract][Full Text] [Related]
8. Nefarious NTRK oncogenic fusions in pediatric sarcomas: Too many to Trk.
Aepala MR; Peiris MN; Jiang Z; Yang W; Meyer AN; Donoghue DJ
Cytokine Growth Factor Rev; 2022 Dec; 68():93-106. PubMed ID: 36153202
[TBL] [Abstract][Full Text] [Related]
9. Treatment Patterns of Real-World Patients with TRK Fusion Cancer Treated by US Community Oncologists.
Klink AJ; Kavati A; Gassama A; Kozlek T; Gajra A; Antoine R
Target Oncol; 2022 Sep; 17(5):549-561. PubMed ID: 36089643
[TBL] [Abstract][Full Text] [Related]
10. The promise of TRK inhibitors in pediatric cancers with NTRK fusions.
Blauel ER; Laetsch TW
Cancer Genet; 2022 Apr; 262-263():71-79. PubMed ID: 35108663
[TBL] [Abstract][Full Text] [Related]
11. Detection of Tumor NTRK Gene Fusions to Identify Patients Who May Benefit from Tyrosine Kinase (TRK) Inhibitor Therapy.
Hsiao SJ; Zehir A; Sireci AN; Aisner DL
J Mol Diagn; 2019 Jul; 21(4):553-571. PubMed ID: 31075511
[TBL] [Abstract][Full Text] [Related]
12. Larotrectinib efficacy and safety in adult patients with tropomyosin receptor kinase fusion sarcomas.
Kummar S; Shen L; Hong DS; McDermott R; Keedy VL; Casanova M; Demetri GD; Dowlati A; Melcón SG; Lassen UN; Leyvraz S; Liu T; Moreno V; Patel J; Patil T; Mallick AB; Sousa N; Tahara M; Ziegler DS; Norenberg R; Arvis P; Brega N; Drilon A; Tan DSW
Cancer; 2023 Dec; 129(23):3772-3782. PubMed ID: 37769113
[TBL] [Abstract][Full Text] [Related]
13. NTRK gene fusion testing and management in lung cancer.
Repetto M; Chiara Garassino M; Loong HH; Lopez-Rios F; Mok T; Peters S; Planchard D; Popat S; Rudzinski ER; Drilon A; Zhou C
Cancer Treat Rev; 2024 Jun; 127():102733. PubMed ID: 38733648
[TBL] [Abstract][Full Text] [Related]
14. Diagnosis and management of tropomyosin receptor kinase (TRK) fusion sarcomas: expert recommendations from the World Sarcoma Network.
Demetri GD; Antonescu CR; Bjerkehagen B; Bovée JVMG; Boye K; Chacón M; Dei Tos AP; Desai J; Fletcher JA; Gelderblom H; George S; Gronchi A; Haas RL; Hindi N; Hohenberger P; Joensuu H; Jones RL; Judson I; Kang YK; Kawai A; Lazar AJ; Le Cesne A; Maestro R; Maki RG; Martín J; Patel S; Penault-Llorca F; Premanand Raut C; Rutkowski P; Safwat A; Sbaraglia M; Schaefer IM; Shen L; Serrano C; Schöffski P; Stacchiotti S; Sundby Hall K; Tap WD; Thomas DM; Trent J; Valverde C; van der Graaf WTA; von Mehren M; Wagner A; Wardelmann E; Naito Y; Zalcberg J; Blay JY
Ann Oncol; 2020 Nov; 31(11):1506-1517. PubMed ID: 32891793
[TBL] [Abstract][Full Text] [Related]
15. Phase separation underlies signaling activation of oncogenic NTRK fusions.
Zhu T; Xie J; He H; Li H; Tang X; Wang S; Li Z; Tian Y; Li L; Zhu J; Zhu G
Proc Natl Acad Sci U S A; 2023 Oct; 120(42):e2219589120. PubMed ID: 37812694
[No Abstract] [Full Text] [Related]
16. The Use of Pan-Tropomyosin Receptor Kinase Immunohistochemistry as a Screening Tool for the Detection of Neurotrophic Tropomyosin-Related Kinase Fusions: Real-World Data from a National Multicentric Retrospective Study.
Van Bockstal MR; Beniuga G; Craciun L; Creytens D; Dedeurwaerdere F; Delvenne P; Demetter P; De Wiest B; Dewinne K; Habran L; Pauwels P; Theate I; Vander Borght S; Van Der Steen K; Weynand B
Pathobiology; 2022; 89(6):393-406. PubMed ID: 35350025
[TBL] [Abstract][Full Text] [Related]
17. Japan society of clinical oncology/Japanese society of medical oncology-led clinical recommendations on the diagnosis and use of tropomyosin receptor kinase inhibitors in adult and pediatric patients with neurotrophic receptor tyrosine kinase fusion-positive advanced solid tumors, cooperated by the Japanese society of pediatric hematology/oncology.
Naito Y; Mishima S; Akagi K; Igarashi A; Ikeda M; Okano S; Kato S; Takano T; Tsuchihara K; Terashima K; Nishihara H; Nishiyama H; Hiyama E; Hirasawa A; Hosoi H; Maeda O; Yatabe Y; Okamoto W; Ono S; Kajiyama H; Nagashima F; Hatanaka Y; Miyachi M; Kodera Y; Yoshino T; Taniguchi H
Int J Clin Oncol; 2020 Mar; 25(3):403-417. PubMed ID: 31974683
[TBL] [Abstract][Full Text] [Related]
18. [NTRK Fusions: A new way of treatment for gastro-intestinal tumor?].
Ouali K; Pellat A; Cohen R; Svrcek M; Penault-Llorca F; André T
Bull Cancer; 2020 Apr; 107(4):447-457. PubMed ID: 32067719
[TBL] [Abstract][Full Text] [Related]
19. Rationale and design of ON-TRK: a novel prospective non-interventional study in patients with TRK fusion cancer treated with larotrectinib.
Yang JCH; Brose MS; Castro G; Kim ES; Lassen UN; Leyvraz S; Pappo A; López-Ríos F; Reeves JA; Fellous M; Penault-Llorca F; Rudzinski ER; Tabatabai G; Vassal G; Drilon A; Trent J
BMC Cancer; 2022 Jun; 22(1):625. PubMed ID: 35672677
[TBL] [Abstract][Full Text] [Related]
20. Canadian Consensus for Biomarker Testing and Treatment of TRK Fusion Cancer in Pediatric Patients.
Perreault S; Chami R; Deyell RJ; El Demellawy D; Ellezam B; Jabado N; Morgenstern DA; Narendran A; Sorensen PHB; Wasserman JD; Yip S
Curr Oncol; 2021 Jan; 28(1):346-366. PubMed ID: 33435412
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
